Overall verdict
Neutral
5.9/10
1-year performance
+60.03%
Score breakdown
Up 60.0% over 1 year, 97% of the 52-week range.
Strongest: Profitability 10.0/10. Weakest: Valuation 0.1/10.
29 analysts, target -0.1% vs the price.
Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as astaxanthin, beta-carotene, lycopene, canthaxanthin, apocarotenal, and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries.
It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.
Sector
Health Care
Industry
Life Sciences Tools and Services
Primary listing
Nse
India
CEO
Kiran Divi
Founded
1990
Employees
19 292
Revenue / employee
5.5M INR
Next earnings
November 4, 2026 (estimated)
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
9740.00 INR
52-week low
5636.50 INR
1-year performance
60.03%
Rising
Year-to-date performance
51.00%
Rising
Drawdown
-1.24%
Near its high
Position in the 52-week range
97% of range
Quality and profitability
10.0/10Gross margin 45.5%, net margin 26.0%.
Net margin
26.05%
Exceptional
Sector 5.47%|S&P 12.97%
Gross margin
45.53%
Fair
Return on equity (ROE)
—
Sector 3.11%|S&P 16.52%
Return on invested capital (ROIC)
—
Free cash flow margin (FCF)
—
Margin stability
4.3 pts
Steady
Revenue to net income
Growth
6.4/10Revenue up 27.8% over 1 year, 8.9% a year over 5, EPS 5.3% a year over 5.
Revenue (trailing 12 months)
112Md INR
Revenue growth (1y)
27.80%
Hyper-growth
Revenue growth (3y)
36.12%
Solid
EPS growth (1y)
65.51%
Hyper-growth
EPS CAGR (5y)
5.29%
Low
EPS revisions (3 months)
7.65%
Sharply revised up
Valuation
0.1/10P/E 87.3x, forward P/E 78.3x, EV/EBITDA 64.3x, PEG 16.50. The multiple sits in the 97th percentile of its own 5-year history.
P/E (TTM)
87.3x
Expensive
Sector 50.2x|S&P 23.0x
Forward P/E
78.3x
Very expensive
EV / EBITDA
64.3x
Very expensive
Sector 28.3x|S&P 14.5x
PEG
16.50
Very expensive
Sector 1.05|S&P 0.86
P/E vs its own 5-year history
among the 3% highest valuations
At its historical high
Market cap
2.6T INR
Financial strength
10.0/10Cash covers 46185.7% of the debt, net debt/EBITDA -1.0x.
Net debt / EBITDA
-1.0x
Net cash
Gearing (net debt / equity)
—
Cash
32.3Md INR
Cash / market cap
1.27%
Stretched
Cash / total debt
46185.71%
Net cash
Net debt
-32.3Md INR
Equity
—
Closed daily candles, 2 years
Last close on September 24, 2026: 9,602.00 INR
- MM209,334.10
- MM508,596.81
- MM2006,961.24
- RSI 1466.7
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+4.40%
200-day average slope, 3 months
+9.45%
50-day average slope, 1 month
+14.14%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.61 % per day
Volatility change
+12.39%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2027 | 122.82 (24) | 123.24 (28) | 125 752 (29) | 45 288 (28) | 32 649 (24) |
Amounts in millions of INR, EPS in INR per share. In brackets, the number of analysts. Consensus as of September 23, 2026.
Same sub-industry: 103 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 603259 | 8.0 | 8.0 | 75.1Md USD | 22.2x | 40.2 % | 47.7 % | 29.5 % | -1.7x | 2.6 % | 56.1 % | ||
| 2 | A207940 | 7.5 | 7.9 | 46.0Md USD | 31.8x | 39.9 % | 30.2 % | 16.6 % | -0.2x | 2.3 % | -13.0 % | ||
| 3 | IQV | 6.8 | 7.0 | 44.1Md USD | 33.2x | 8.1 % | 8.8 % | 6.8 % | 4.1x | 5.0 % | 47.6 % | ||
| 4 | DHR | 6.4 | 6.5 | 156Md USD | 39.3x | 15.9 % | 5.5 % | 5.4 % | 2.0x | 3.5 % | 18.6 % | ||
| 5 | A | 6.3 | 6.5 | 46.6Md USD | 32.5x | 19.5 % | 8.1 % | 13.9 % | 0.9x | 2.7 % | 38.1 % | ||
| 6 | LONN | 6.3 | 6.1 | 46.4Md USD | Not meaningful (loss) | 16.7 % | 19.2 % | 8.7 % | 1.9x | 0.6 % | 6.1 % | ||
| 7 | DIVISLAB | 5.9 | 5.7 | 26.6Md USD | 87.3x | 26.0 % | 27.8 % | — | -1.0x | — | 60.0 % | ||
| 8 | TMO | 5.9 | 5.7 | 246Md USD | 35.8x | 15.0 % | 10.5 % | 7.9 % | 2.8x | 3.0 % | 45.0 % | ||
| 9 | WAT | 4.3 | 3.0 | 41.3Md USD | 105.0x | 3.6 % | 113.3 % | 1.4 % | 0.8x | 0.9 % | 44.7 % |
